Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.

AIM Irinotecan is an active drug after fluorouracil (FU) failure in patients with colorectal cancer (CRC). Also a modest activity of cisplatin and dacarbazine combination in FU resistant patients have been reported. We aimed to assess the efficacy of irinotecan, cisplatin and dacarbazine combination in previously treated patients with measurable advanced CRC. METHODS Treatment schedule was irinotecan 150 mg/m2, iv, d1; cisplatin 20 mg/m2 and dacarbazine 200 mg/m2 iv, d1-d3; every 21 days. 48 patients with a median age of 51 were entered the study. RESULTS Objective response rate was 33.3%. The overall disease stabilization rate was 75.6%. The median survival was 14 months, and the median progression-free survival was 7 months. Main toxicities were grade 2-3 vomiting (39.2%) and grade 3-4 neutropenia (17.4%). CONCLUSION CPD combination seems to be very active, with acceptable safety profile, in patients with advanced CRC resistant to FUFA.

[1]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[2]  A. Avallone,et al.  Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[4]  A. Arıcan,et al.  Phase II Study of Cisplatin and Dacarbazine for Metastatic Colorectal Carcinoma Resistant to 5-Fluorouracil , 1999, Oncology.

[5]  H. Bleiberg.  CPT-11 in gastrointestinal cancer. , 1999, European journal of cancer.

[6]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[7]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[8]  C. Punt.  New drugs in the treatment of colorectal carcinoma , 1998, Cancer.

[9]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[10]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[12]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .